ArriVent BioPharma Inc. (AVBP) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

The Roarable RQD assigns AVBP a score of 29 out of 100, a letter grade of E, and a verdict of "Roarable Strong Sell — Forensic Risk / Avoid." Across its five pillars, the fundamental cash engine scores 6/20 (ROIC of -35% and FCF yield of -20.42%), indicating that the company is consuming rather than generating cash relative to its market value. Whale 13F flow scores 3/20 and insider conviction scores 3/20, per the Roarable RQD rating, signaling weak institutional and insider support in the source data. Macro regime fit scores 7/20 with a beta of 1.0, meaning the stock's sensitivity to the broader market is average, but the sector-sensitivity component still weighs against it. Forensic balance sheet scores 10/20, reflecting an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a debt-to-equity ratio of 0.5. For a prospective investor, the practical implication is that upside would have to come from clinical or regulatory outcomes not captured in these cash and balance-sheet metrics, while valuation support from current cash generation is negative. This is an analytical reading of the rating, not personalized advice.

Per the SEC financials, AVBP reported zero revenue across all three periods, with operating losses widening from $-74.6M (FY 2023) to $-177.5M (FY 2025). Gross, operating, and net margins are each reported as 0% in the market data, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, per the Roarable RQD rating, with a debt-to-equity ratio of 0.5. Cash declined from $74.3M in FY 2024 to $45.5M in FY 2025 per the SEC financials.

The news wire contains six items, all dated within the last 15 hours of the data timestamp. Three are tagged RISK WATCH and tied to trial outcomes: a Fierce Biotech report describes a phase 3 lung cancer trial as failing, an Investing.com report describes a 60% stock decline after a trial missed its primary endpoint, and a TradingView report describes a 12-month price target cut to $37.55, implying 32% upside. A Seeking Alpha item similarly attributes a plunge to a cancer trial failure. A Benzinga item asks why the stock is tumbling, and a Yahoo Finance Singapore item is a general market-action piece. The butterfly supply-chain graph reports no supply-chain links and no proprietary signals. The clinical-trial failure is the dominant catalyst in the source data, though the exact trial details are Not available in source data beyond the headlines.

• What were the specific endpoints, patient populations, and regulatory implications of the phase 3 lung cancer trial referenced in the news wire?
• What is the company's cash runway given cash of $45.5M against FY 2025 operating losses of $-177.5M?
• What are AVBP's product pipeline, partnership, or licensing arrangements, and do any generate revenue?
• What is the consensus analyst rating and price-target distribution, given the 12-month target cut to $37.55 referenced in the news wire?
• What do institutional and insider holdings look like, and have any 13F or Form 4 filings occurred?